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Abstract
Post-transplant lymphoproliferative disorders comprise a spectrum of reactive to neoplastic lymphoid
proliferations that occur in organ transplant recipients as a result of the iatrogenic immuno-
suppression. They usually appear within 1 year after the transplant, although they can sometimes
occur after a long interval. Most cases are B-cell proliferations that are driven by Epstein-Barr
virus, and the major types are 1. early lesions (plasmacytic hyperplasia and infectious
mononucleosis-like lesion), which are usually polyclonal; 2. polymorphic post-transplant
lymphoproliferative disorders, which are usually oligoclonal or monoclonal; and 3. monomorphic
post-transplant lymphoproliferative disorders, which are morphologically identical to conventional
lymphomas, are monoclonal, and commonly exhibit structural alterations in oncogenes and tumor-
suppressor genes. Early lesions and a proportion of polymorphic post-transplant lymphoproliferative
disorders regress with reduction in immunosuppressants, whereas almost all monomorphic post-
transplant lymphoproliferative disorders progress and require lymphoma-type treatment.
Key words: B-lymphocytes/pathology, Immunosuppression, Lymphoma, Lymphoproliferative disorders,
Transplantation
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INTRODUCTION
Organ transplant recipients are at an increased risk of
developing malignancies, in particular lymphomas
(lymphoproliferative disorders), skin cancer, and Kaposi
sarcoma. The emergence of malignancies results from
reduced host immune surveillance because of the
inevitable need to take immunosuppressants to prevent
graft rejection. It is important to recognize post-transplant
lymphoproliferative disorders (PTLDs) because some
lesions can show dramatic regression with reduction or
cessation of immunosuppression, and thus do not require
aggressive treatment as used for lymphomas (1).
WHAT IS POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISORDER?
Post-transplant lymphoproliferative disorder is a
lymphoid cell proliferation affecting organ transplant
recipients (2). The majority of cases is of B lineage, and
is driven by Epstein-Barr virus (EBV). The designation
“lymphoproliferative disorder” is used instead of an
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lung transplant is probably attributable to the relat-
ively high intensity of immunosuppressive regime,
propensity to develop severe infections and/or
rejection, and frequent occurrence of primary EBV
infection.
2. Immunosuppressive regimes–the more profound the
immunosuppressive regime, the higher the risk. For
example, adding OKT3 to treat graft rejection episodes
is associated with a particularly high risk of PTLD,
which can develop after a remarkably short interval.
When cyclosporin was first used as an immuno-
suppressive agent for organ transplant recipients, the
incidence of PTLD increased to 9% to 13%; but with
the use of lower doses through close monitoring of
the cyclosporin blood levels, the incidence has dropped
dramatically to 1% to 2% in recent years. The use of
tacrolimus as an immunosuppressant seems to be
associated with a higher risk of developing PTLD
compared with the use of cyclosporin, but perhaps
careful monitoring of the drug level can help to bring
down the incidence (13,14).
3. Age of patient–children are at higher risk of developing
PTLD, probably because they are more often sero-
negative for EBV before transplantation (12,14,15).
4. Primary infection of EBV (first exposure) after
transplantation–thus, seronegativity for EBV before
transplantation is a high-risk factor for development
of PTLD (16,17).
WHEN DOES POST-TRANSPLANT
LYMPHOPROLIFERATIVE
DISORDER OCCUR?
Most PTLDs develop within several months to 1 year
after the transplant, with the reported median interval
being 4.5 to 11 months. Use of cyclosporin is associated
with the development of PTLD at a shorter time interval
after transplantation. Rarely, PTLD can develop late;
such late-occurring PTLDs are more likely than early-
occurring PTLDs to be EBV negative (11,12).
WHAT ARE THE PREDILECTION
SITES?
The preferred sites of involvement in PTLD are the
allograft and various extranodal sites, such as the
gastrointestinal tract, central nervous system, liver, and
lung (Fig. 1) (12). Lymph nodes can also be involved.
The pattern of organ involvement may differ according
to the immunosuppressive regime. In patients receiving
an azathioprine-based regime, PTLDs often involve
extranodal sites, such as the allograft and central nervous
system. In patients receiving cyclosporin or tacrolimus,
the PTLDs tend to involve lymph nodes and gastro-
intestinal tract (11).
outright “lymphoma” because the lymphoid lesions are
not always clonal (neoplastic), and the morphologic
features often differ from those of lymphomas occurring
in non-immunocompromised hosts (3,4).
Post-transplant lymphoproliferative disorders can also
occur in recipients of bone marrow transplant (5). The
differences from PTLDs occurring in solid organ trans-
plant recipients include the following (6,7): 1. younger
age group; 2. shorter interval between transplantation and
development of PTLD (median, 52-101 days); 3. almost
consistent association with EBV; 4. lack of correlation
between histologic appearance and molecular evidence
of clonality; and 5. very aggressive clinical course. The
risk of developing PTLD is particularly high for those
who receive T cell-depleted allogeneic grafts (8).
The literature on PTLD is confusing because different
terms and classifications have been used by different
authors (3,9,10). Some authors used the term PTLD as
an umbrella term to encompass the entire spectrum of
lymphoid proliferations in the post-transplant setting, and
this is also the recommended terminology of the latest
World Health Organization classification of hema-
topoietic and lymphoid tumors (11). Some restricted the
term for lymphoid hyperplasias and polymorphic
lymphoproliferations; and still others used the term for
polymorphic lymphoid proliferations only.
HOW HIGH IS THE RISK OF
DEVELOPING POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISORDER
IN AN ORGAN TRANSPLANT
RECIPIENT?
The overall risk of developing PTLD in organ transplant
recipients is approximately 1.7%. However, it is difficult
to estimate the risk for an individual patient because many
factors can influence the magnitude of the risk, such as
the following:
1. Nature of transplant (Table 1) (12)–the reported risk
of developing PTLD varies with the nature of
transplant, and is low for renal transplant (approx-
imately 1%). The high risk seen in patients with heart-
Table 1. Overall risks of developing post-transplant lympho-
proliferative disorder in transplant recipients.
Type of organ transplant Reported risk of developing PTLD (%)
Kidney 1
Liver 2
Heart 1.8-9.8
Heart and lung 4.6-9.4
Bone marrow 0.6-7.4
PTLD = post-transplant lymphoproliferative disorder
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HOW DOES POST-TRANSPLANT
LYMPHOPROLIFERATIVE
DISORDER MANIFEST
CLINICALLY?
Patients with PTLD usually present with one of the
following three clinical patterns (18): 1. infectious
mononucleosis-like, characterized by prominent cervical
lymphadenopathy, pharyngitis, and fever. This
presentation is most often seen in young patients, and
occurs soon after transplantation. The disease is usually
self-limiting, but some cases can prove fatal; 2. effects
or complications of mass lesions, such as in the allograft,
gastrointestinal tract, liver, lung, and central nervous
system; and 3. allograft failure because of involvement
of the allograft by PTLD. This presentation of PTLD
can mimic that of graft rejection.
WHAT ARE THE PATHOGENETIC
MECHANISMS?
To understand the pathogenesis of PTLD, it is essen-
tial to know the immune regulation of infectious
mononucleosis, which is a self-limiting EBV-associated
lymphoproliferative disorder. As a primary infection,
EBV infects and immortalizes B cells, causing them to
proliferate profusely. The host mounts an EBV-specific
T-cell response to control the B-cell proliferation, with
the cytotoxic T cells killing the B cells. As a result, the
lymphoproliferative process subsides (Fig. 2).
Post-transplant lymphoproliferative disorders can be
imagined as infectious mononucleosis gone astray (19).
Primary infection by EBV or reactivation of latent EBV
infection results in marked B-cell proliferation. In organ
transplant recipients, the T-cell response is attenuated
because of the inevitable use of immunosuppressants.
As a result, there are insufficient host T cells to control
the B-cell proliferation, which then proceeds unchecked
(Fig. 3). The EBV-positive B cells can accumulate in
various sites of the body and form mass lesions. The
process progresses from a polyclonal proliferation, to
an oligoclonal proliferation, and eventually to a mono-
clonal proliferation (neoplasm) (Fig. 4). In the early
phases, restoration of the immune competence (such as
by reduction or cessation of immunosuppressive therapy)
can lead to reversal of the process, because the increased
cytotoxic T cells can recontrol the B-cell proliferation.
However, with subsequent emergence of subclones that
have growth advantage because of mutations in the
various proto-oncogenes and tumor suppressor genes,
that is, development of frank lymphoma with auto-
nomous growth, even restoration of immune competence
will not be able to reverse the lymphoproliferative
process. Thus, like other malignant neoplasms, the
genesis of PTLD is a multistep process (20).
When a patient develops multiple PTLD lesions in the
same organ, in several anatomic sites, or at different time
Figure 1. Polymorphic post-transplant lymphoproliferative disorder
involving the large intestine. The intestinal tract is a common site
for involvement. (A) The large intestinal mucosa and wall show
dense infiltration by lymphoid cells. Note the destruction of the
mucosal glands by the infiltrate. (B) The infiltrate comprises a
mixture of large cells and plasma cells.
Figure 2. Schematic diagram showing the cellular interplay in
infectious mononucleosis.
EBV = Epstein-Barr virus
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points, the lesions can represent the same clonal process
or multiple independent distinct clonal processes (21,22).
IS EPSTEIN-BARR VIRUS
ESSENTIAL FOR DEVELOPMENT
OR DIAGNOSIS OF POST-
TRANSPLANT LYMPHO-
PROLIFERATIVE DISORDER?
Although EBV takes a key role in the development of
PTLD, 10% to 20% of PTLDs are negative for EBV (11,
20,23). Of interest, the proportion of EBV-negative
PTLDs seems to have increased in recent years (24,25).
Such PTLDs have the following characteristics (23,24):
1. occurring at a longer interval after transplantation
(median, 50 months vs 10 months for EBV-positive
cases); 2. more likely to show a monomorphic mor-
phology (67% vs 42% for EBV-positive cases); and 3.
generally more aggressive, that is, poor response even
with aggressive therapy.
Nonetheless, some (approximately 23%) patients with
EBV-negative PTLDs  do show remission with reduction
of immunosuppression (24). Thus, EBV positivity is
neither a prerequisite for the diagnosis of PTLD, nor can
it predict whether a lesion will or will not respond to
reduction of immunosuppression. Of interest, human
herpesvirus type 8 has recently been implicated in an
example of PTLD (25). Further studies are needed to
determine its role, if any, in the genesis of PTLDs.
IS THE LYMPHOPROLIFERATIVE
DISORDER OF DONOR OR HOST
ORIGIN?
The donor-versus-host origin of PTLD arising in solid
organ transplant recipients remains a controversial issue.
Whereas some studies suggest that the majority of PTLDs
are of host origin (26,27), recent studies suggest that most
cases are of donor origin (28-31).
WHAT ARE THE PATHOLOGIC
FINDINGS?
The histologic findings are variable, depending on the
type of PTLD. The latest World Health Organization
classification scheme of hematolymphoid neoplasms is
listed in Table 2 (11). The clinicopathologic features of
the major types of PTLDs are listed in Table 3 (Figs. 5
and 6) (32). One form of PTLD can progress to another,
for example, polymorphic PTLD can transform to
monomorphic PTLD.
It is important to realize that the term “polymorphic”
refers to the presence of a spectrum of lymphoid cells
that recapitulate the development of B lymphocytes
(lymphocyte ⇒ immunoblast ⇒ plasmablast ⇒ plasma
cell), but not a pleomorphic population of atypical cells
with significant variation in size and shape. In the latter
circumstance, the lesion should be classified as a
“monomorphic PTLD” (33). Earlier studies indicate that
only approximately half of the cases of polymorphic
PTLDs are monoclonal (9,34), but more recent studies
have shown that the great majority of cases are mono-
clonal (20,32,35). Monomorphic PTLDs are almost
always monoclonal.
Rare types of PTLDs include plasmacytoma, Hodgkin
lymphoma, peripheral T-cell lymphoma, and natural
killer-cell lymphoma (36-41). Peripheral T-cell
lymphomas usually develop after a long latent interval
(median, 5 years), rarely involve the allograft, show
association with EBV in only approximately 50% of
cases, and only infrequently respond to decreased
immunosuppression (11,20,42).
Figure 4. Evolution of the various types of post-transplant
lymphoproliferative disorders. With time, a monoclonal population
emerges. Selection of a subclone with growth advantage because
of mutations in oncogenes or tumor suppressor genes results in
autonomous growth.
PTLD = post-transplant lymphoproliferative disorder
Figure 3. Schematic diagram showing the cellular interplay in the
development of post-transplant lymphoproliferative disorder.
EBV = Epstein-Barr virus; PTLD = post-transplant lympho-
proliferative disorder
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WHAT INFORMATION CAN BE
EXPECTED FROM PATHOLOGIC
EXAMINATION OF LESIONS
SUSPECTED TO REPRESENT
POST-TRANSPLANT
LYMPHOPROLIFERATIVE
DISORDER?
Pathologic examination of the biopsy or excision speci-
men is required to determine the histologic diagnosis.
The major diagnostic possibilities are: 1. PTLD; 2. graft
rejection. Histologically, it is not always easy to make a
distinction between graft rejection and early involvement
of the allograft by PTLD (Fig. 7A). In general, B cells
predominate in PTLD, whereas T cells (mostly cytotoxic
T cells) predominate in graft rejection. In situ
hybridization for EBV early RNAs usually shows
numerous positive cells in PTLD, whereas there are no
or few positive cells in graft rejection (Fig. 7B); 3.
infection; 4. other immunosuppression-associated
neoplasms, such as Kaposi sarcoma and EBV-positive
post-transplant smooth muscle tumor; and 5. other
incidental pathologic processes unrelated to the immuno-
suppression.
If a diagnosis of PTLD is confirmed, the following
information will help to predict the outcome and guide
the treatment:
1. Type of PTLD (Tables 2 and 3)–according to one
study, no patients with plasmacytic hyperplasia died,
Table 3. Clinicopathologic features of major types of post-transplant lymphoproliferative disorder (2,32).
Type
Early lesions (plasmacytic
  hyperplasia and infectious
  mononucleosis-like)
Polymorphic PTLD
Monomorphic PTLD
Clinical features
Usually affects children and young
  adults not previously exposed to EBV
Often appears soon after transplantation
Involves lymph nodes and tonsils
Lesion often regresses spontaneously or
  with minimal reduction in  immuno-
  suppressant
Affects all age groups
Disease involves lymph node, lung,
  gastrointestinal tract, or allograft
A proportion of cases regresses with
  reduction of immunosuppression,
  but some cases do progress
Affects all age groups
Disease involves lymph node, bone
  marrow, or various extranodal sites
Disease often disseminated at pre-
  sentation
Most cases show rapid progression, and
  only rare cases respond to reduction
  in immunosuppression
Pathologic features
Tissue architecture at least partially
   preserved
Proliferated cells do not exhibit atypia
Plasma cells and lymphoplasmacytoid
cells predominate in plasmacytic
hyperplasia; and more immunoblasts
and plasmablasts are seen in infect-
  ious mononucleosis-like lesion
Tissue architecture effaced
Mixture of small lymphocytes, plasma
  cells, and large activated cellsrecapitu-
  lating the full spectrum of B lympho-
  cyte maturation.
Large cells may show atypia.
Necrosis is variable
Tissue architecture effaced
Monotonous infiltrate similar to the
  usual lymphomas, most commonly
  large B-cell lymphoma
Geographic necrosis is common
Molecular features
Polyclonal Ig gene in most
   cases
EBV usually nonclonal
Ig gene usually monoclonal,
  but sometimes oligoclonal or
  polyclonal
EBV clonal
Usually no structural
  alterations in oncogenes and
  tumor suppressor genes
Monoclonal Ig gene in all
  cases
EBV clonal
Frequently shows structural
  alterations in various
  oncogenes and tumor
  suppressor genes, such as
  c-myc, p53, and N-ras.
EBV = Epstein-Barr virus; Ig = immunoglobulin; PTLD = post-transplant lymphoproliferative disorder
Table 2. Post-transplant lymphoproliferative disorders (World Health Organization classification of tumors of hematopoietic and lymphoid
tissues, 2001).
1. Early lesions
- Reactive plasmacytic hyperplasia
- Infectious mononucleosis-like
2. Polymorphic PTLD
3. Monomorphic PTLD (classify according to conventional lymphoma classification)
- B-cell neoplasms (eg, diffuse large B-cell lymphoma, Burkitt lymphoma, plasma cells myeloma, plasmacytoma-like lesions)
- T-cell and natural killer cell neoplasms (eg, peripheral T-cell lymphoma not otherwise specified, hepatosplenic γδ T-cell lymphoma,
        natural killer cell lymphoma)
4. Hodgkin lymphoma and Hodgkin lymphoma-like PTLD
PTLD = post-transplant lymphoproliferative disorder
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A B C
Figure 6. Monomorphic post-transplant lymphoproliferative disorder  (large B-cell lymphoma) involving the brain. (A) There is a monotonous
population of abnormal large lymphoid cells. (B) Geographic necrosis is a common feature.
A B
A B C
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whereas death occurred in 20% and 67% of patients
with polymorphic PTLD and monomorphic PTLD,
respectively (43). Nonetheless, there can be variability
in the nature of the lesions at different sites in the
same patient; for example, biopsy at one site may show
polymorphic PTLD, whereas biopsy at another site
may reveal monomorphic PTLD (33). Thus, multiple-
site biopsies are advisable if there are multiple lesions,
unless one biopsy already shows a “worst” lesion
(monomorphic PTLD).
2. Oncogene mutations–it is difficult to predict
precisely in an individual patient whether the PTLD
will regress with reduction of immunosuppression.
According to one study, the presence of bcl-6 gene
mutation (found in 0% of early lesions, 45% of
polymorphic PTLDs, and 90% of monomorphic
PTLDs) predicts shortened survival and lack of
regression after reduction in immunosuppression and/
or surgical excision, irrespective of the morphologic
category (44). However, another study reports bcl-6
mutation in only 25% of polymorphic PTLDs and 25%
of monomorphic PTLDs, and lack of significant
impact on survival (45). More studies are required to
determine the clinical and biologic significance of bcl-
6 mutation.
Increased age, elevated LDH level, severe organ
dysfunction, presence of B symptoms (fever, night
sweats, and weight loss), and multiorgan involvement
by PTLD at the time of diagnosis have been shown to be
independent indicators for poor survival (14,46).
HOW CAN POST-TRANSPLANT
LYMPHOPROLIFERATIVE
DISORDER BE TREATED?
In the early phases of development, restoration of the T-
cell response by various means can potentially reverse
the process because the proliferated B cells can still be
controlled by the T cells. This can be achieved by the
reduction or cessation of immunosuppression (46),
infusion of autologous lymphokine-activated killer cells
(47-49), or infusion of unirradiated donor leukocytes (to
supply cytotoxic T cells presensitized to EBV). The latter
is effective in treating PTLD in allogeneic marrow
transplant recipient (50).
Simultaneous antiviral therapy can also be helpful (51).
The reported complete response rate to reduction of
immunosuppression ranges from 30% to 80% (14).
However, when the process is more advanced, with
alterations of oncogenes and tumor suppressor genes,
the B-cell proliferation becomes autonomous, and
restoration of the host immune system will not be able
to reverse the process. In such circumstance, the PTLD
Figure 7. Post-transplant lymphoproliferative disorder involving allograft (kidney). (A) In contrast to graft rejection, there is
no tubulitis (infiltration of tubular epithelium by lymphoid cells). (B) In situ hybridization for  Epstein-Barr virus encoded RNA
shows numerous positive cells (nuclear staining), further supporting a diagnosis of post-transplant lymphoproliferative
disorder over graft rejection.
A B
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has to be treated as for conventional lymphoma, such as
surgical excision, chemotherapy, and radiotherapy. There
have also been some successes with the use of the
humanized anti-CD20 antibody Rituximab, other anti-B
cell monoclonal antibodies, or interferon alpha (52-57).
In summary, in the management of PTLD, the best results
are obtained if an early diagnosis can be made, and
appropriate treatment is given accordingly (11). In
practical terms, except for monomorphic PTLD showing
rapid tumor progression, the patient can be observed for
1 or 2 weeks to see whether there is disease regression
upon withdrawing or decreasing the immunosuppressant
(21). This plan of treatment can be continued if there is
evidence of regression. If the disease progresses,
aggressive therapy as for lymphoma has to be initiated.
CAN POST-TRANSPLANT
LYMPHOPROLIFERATIVE
DISORDER BE PREVENTED?
Only a small fraction of organ transplant recipients
develops PTLD. The incidence can potentially be re-
duced by targeting the known high-risk group. Careful
adjustment of the immunosuppressant dose to a low level
just sufficient to prevent graft rejection can reduce the
risk. Prophylactic antiviral therapy (such as ganciclovir
and acyclovir) can be considered whenever anti-
lymphocyte globulin has to be used to treat episodes of
graft rejection (58). Careful monitoring of the EBV load,
such as using quantitative polymerase chain reaction
technique, can potentially help in identifying early
development of PTLD, especially for patients that are
seronegative for EBV before transplantation (59).
REFERENCES
1. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP,
Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, Atchison RW,
Jaffe R, Bahnson HT. Reversibility of lymphomas and lympho-
proliferative lesions developing under cyclosporin-steroid therapy.
Lancet 1984;1:583-7.
2. Chan JKC. Tumors of the lymphoreticular system, including spleen
and thymus. In: Fletcher CDM, ed. Diagnostic histopathology of
tumors. 2nd ed. London: Churchill Livingstone; 2000:1099-316.
3. Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW,
Sibley RK, Holahan KP, Lindquist LL. Polymorphic diffuse B-cell
hyperplasias and lymphomas in renal transplant recipients. Cancer
Res 1981;41:4262-79.
4. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL,
Saemundsen AK, Klein G, Simmons RL. Clinical spectrum of
lymphoproliferative disorders in renal transplant recipients and
evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:
4253-61.
5. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks
PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner
DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP,
Hoover RN, Fraumeni JF Jr, Deeg HJ. Risk of lymphoproliferative
disorders after bone marrow transplantation: a multi-institutional
study. Blood 1999;94:2208-16.
6. Chadburn A, Frizzera G, Pan L, Shulman H, Knowles DM. Post-
transplantation lymphoproliferative disorders in bone marrow
transplant and solid organ transplant recipients [abstract]. Mod
Pathol 2000;13:144A.
7. Graczyk MJ, Landre JK, Manivel JC, Coad JE. Post-transplant
lymphomas: a comparison of solid organ and bone marrow
transplantation cases [abstract]. Mod Pathol 2000;13:149A.
8. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH,
Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay
NK, McGlave P, Filipovich AH. Epstein-Barr virus associated B cell
lymphoproliferative disorders following bone marrow transplantation.
Blood 1988;71:1234-43.
9. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham
JA, Makowka L, Ho M, Locker J. The pathology of posttransplant
lymphoproliferative disorders occurring in the setting of cyclosporine
A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
10.Swerdlow SH. Classification of the posttransplant lympho-
proliferative disorders: from the past to the present. Semin Diagn
Pathol 1997;14:2-7.
11. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant
lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H,
Vardiman JW, eds. Pathology and genet ics,  tumors of
haematopoietic and lymphoid tissues, World Health Organization
classification of tumours. Lyon: IARC Press; 2001:164-269.
12.Nalesnik MA, Frizzera G. Posttransplant lymphoproliferative
disorders. In: Weiss LM, ed. Pathology of lymph nodes, contem-
porary issues in surgical pathology. Vol. 21. New York: Churchill
Livingstone; 1996:345-79.
13.Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon
WE. Risk factors for posttransplant lymphoproliferative disorder
(PTLD) in pediatric kidney transplantation: a report of the North
American Pediatric Renal Transplant Cooperative Study
(NAPRTCS). Transplantation 2001;71:1065-8.
14.Frizzera G. Atypical lymphoproliferative disorders. In: Knowles DM,
ed. Neoplastic hematopathology. 2nd ed. Philadelphia: Lippincott
Williams & Wilkins; 2001:569-622.
15.Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L,
Atchison RW, Karrer F, Nalesnik MA, Starzl TE. The frequency of
Epstein-Barr virus infection and associated lymphoproliferative
syndrome after transplantation and its manifestations in children.
Transplantation 1988;45:719-27.
16.Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH,
Velosa JA, Habermann TM, Daly RC. Pretransplantation sero-
negative Epstein-Barr virus status is the primary risk factor for
posttransplantation lymphoproliferative disorder in adult heart, lung,
and other solid organ transplantations. J Heart Lung Transplant
1995;14:214-21.
17.Levine SM, Angel L, Anzueto A, Susanto I, Peters JI, Sako EY,
Bryan CL. A low incidence of posttransplant lymphoproliferative
disorder in 109 lung transplant recipients. Chest 1999;116:1273-7.
18.Flinner RL. Neoplasms occurring in solid organ transplant recipients.
In: Hammond EH, ed. Solid organ transplantation pathology. Major
problems in pathology. Vol. 30. Philadelphia: WB Saunders; 1994:
262-73.
19.Nalesnik MA, Starzl TE. Epstein-Barr virus, infectious mono-
nucleosis, and posttransplant lymphoproliferative disorders.
Transplant Sci 1994;4:61-79.
20.Knowles DM. Immunodeficiency-associated lymphoproliferative
65
Hong Kong J Nephrol 2001;3(2):57-66. JKC CHAN
disorders. Mod Pathol 1999;12:200-17.
21.Chadburn A, Cesarman E, Knowles DM. Molecular pathology of
posttransplantation lymphoproliferative disorders. Semin Diagn
Pathol 1997;14:15-26.
22.Wu TT, Swerdlow SH, Locker J, Bahler D, Randhawa P, Yunis EJ,
Dickman PS, Nalesnik MA. Recurrent Epstein-Barr virus-associated
lesions in organ transplant recipients. Hum Pathol 1996;27:157-
64.
23.Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L,
Gandjbakhch I ,  B inet  JL ,  Raphael  M.  Post t ransp lant
lymphoproliferative disorders not associated with Epstein-Barr virus:
a distinct entity? J Clin Oncol 1998;16:2052-9.
24.Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow
SH. Epstein-Barr virus-negative post-transplant lymphoproliferative
disorders: a distinct entity? Am J Surg Pathol 2000;24:375-85.
25. Kapelushnik J, Ariad S, Benharroch D, Landau D, Moser A, Delsol
G, Brousset P. Post renal transplantation human herpesvirus 8-
associated lymphoproliferative disorder and Kaposi's sarcoma. Br
J Haematol 2001;113:425-8.
26.Randhawa PS, Yousem SA. Epstein-Barr virus-associated
lymphoproliferative disease in a heart-lung allograft. Demonstration
of host origin by restriction fragment-length polymorphism analysis.
Transplantation 1990;49:126-30.
27.Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro
I. Posttransplantation lymphoproliferative disorders in solid organ
recipients are predominantly aggressive tumors of host origin. Am
J Clin Pathol 1995;103:748-55.
28.Ng IO, Shek TW, Thung SN, Ye MM, Lo CM, Fan ST, Lee JM,
Chan KW, Cheung AN. Microsatellite analysis in post-trans-
plantation lymphoproliferative disorder to determine donor/recipient
origin. Mod Pathol 2000;13:1180-5.
29.Baron PW, Heneghan MA, Suhocki PV, Nuckols JD, Tuttle-Newhall
JE, Howell DN, Clavien PA. Biliary stricture secondary to donor B-
cell lymphoma after orthotopic liver transplantation. Liver Transpl
2001;7:62-7.
30.Lones MA, Lopez-Terrada D, Weiss LM, Shintaku IP, Said JW.
Donor origin of posttransplant lymphoproliferative disorder localized
to a liver allograft: demonstration by fluorescence in situ
hybridization. Arch Pathol Lab Med 1997;121:701-6.
31.Hegele RG, Bicknell SG, Bailey DJ, Cameron RG. In situ
hybridization for the Y chromosome reveals a donor origin for a
posttransplant lymphoproliferative disorder in a sex-mismatched
hepatic allograft. Arch Pathol Lab Med 1994;118:795-6.
32. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose
EA, Michler RE. Correlative morphologic and molecular genetic
analysis demonstrates three distinct categories of posttrans-
plantation lymphoproliferative disorders. Blood 1995;85:552-65.
33.Harris NL, Ferry JA, Swerdlow SH. Posttransplant lympho-
proliferative disorders: summary of Society for Hematopathology
Workshop. Semin Diagn Pathol 1997;14:8-14.
34.Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of
transplant-associated lymphoproliferations based on the structure
of the genomic termini of the Epstein-Barr virus. Blood 1988;72:
349-52.
35.Knowles DM. Molecular pathology of acquired immunodeficiency
syndrome-related non-Hodgkin's lymphoma. Semin Diagn Pathol
1997;14:67-82.
36.Kraus MD, Crawford DF, Kaleem Z, Shenoy S, MacArthur CA,
Longtine JA. T gamma/delta hepatosplenic lymphoma in a heart
transplant patient after an Epstein-Barr virus positive lympho-
proliferative disorder: a case report. Cancer 1998;82:983-92.
37.Kumar S, Kumar D, Kingma DW, Jaffe ES. Epstein-Barr virus-
associated T-cell lymphoma in a renal transplant patient. Am J
Surg Pathol 1993;17:1046-53.
38.Ulr ich W, Chott A, Watschinger B, Reiter C, Kovarik J,
Radaszkiewicz T. Primary peripheral T cell lymphoma in a kidney
transplant under immunosuppression with cyclosporine A. Hum
Pathol 1989;20:1027-30.
39. van Gorp J, Doornewaard H, Verdonck LF, Klopping C, Vos PF,
van den Tweel JG. Posttransplant T-cell lymphoma. Report of three
cases and a review of the literature. Cancer 1994;73:3064-72.
40.Wu H, Wasik MA, Przybylski G, Finan J, Haynes B, Moore H,
Leonard DG, Montone KT, Naji A, Nowell PC, Kamoun M,
Tomaszewski JE, Salhany KE. Hepatosplenic gamma-delta T-cell
lymphoma as a late-onset posttransplant lymphoproliferative
disorder in renal transplant recipients. Am J Clin Pathol 2000;113:
487-96.
41.Kwong YL, Lam CC, Chan TM. Post-transplantation lympho-
proliferative disease of natural killer cell lineage: a clinico-
pathological and molecular analysis. Br J Haematol 2000;110:197-
202.
42. van Gorp J. Posttransplant T-cell lymphoma: a review. Adv Anat
Pathol 1995;2:132-4.
43.Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett
TJ, Mears JG, Zangwill SD, Addonizio LJ, Michler RE, Knowles
DM. The morphologic and molecular genetic categories of
posttransplantation lymphoproliferative disorders are clinically
relevant. Cancer 1998;82:1978-87.
44.Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R,
Knowles DM. BCL-6 gene mutations in posttransplantation
lymphoproliferative disorders predict response to therapy and
clinical outcome. Blood 1998;92:2294-302.
45.Greiner TC, Huang J, Demidovich Y, Chan WC. Bcl-6 mutations in
posttransplant lymphoproliferative disorders may not predict
survival [abstract]. Mod Pathol 2000;13:149A.
46.Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer
BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA.
Reduction in immunosuppression as initial therapy for post-
transplant lymphoproliferative disorder: analysis of prognostic
variables and long-term follow-up of 42 adult patients. Trans-
plantation 2001;71:1076-88.
47.Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ,
Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE. Autologous
lymphokine-activated killer cell therapy of Epstein-Barr virus-
positive and -negative lymphoproliferative disorders arising in organ
transplant recipients. Transplantation 1997;63:1200-5.
48.Nalesnik MA, Rao AS, Zeevi A, Fung JJ, Pham S, Furukawa H,
Gritsch A, Klein G, Starzl TE. Autologous lymphokine-activated killer
cell therapy of lymphoproliferative disorders arising in organ
transplant recipients. Transplant Proc 1997;29:1905-6.
49.Li PK, Tsang K, Szeto CC, Wong TY, To KF, Leung CB, Lui SF, Yu
S, Lai FM. Effective treatment of high-grade lymphoproliferative
disorder after renal transplantation using autologous lymphocyte
activated killer cell therapy. Am J Kidney Dis 1998;32:813-9.
50.Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad
F, Carabasi MH. Infusions of donor leukocytes to treat Epstein-
Barr virus-associated lymphoproliferative disorders after allogeneic
bone marrow transplantation. N Engl J Med 1994;330:1185-91.
51.Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant
lymphoproliferative disorder in pediatric renal transplantation.
Pediatr Nephrol 1999;13:748-54.
52.Antoine C, Garnier JL, Duboust A, Bariety J, Stevenson G, Glotz
66
Post-transplant lymphoproliferative disorders
D. Successful treatment of posttransplant lymphoproliferative
disorder with renal graft preservation by monoclonal antibody
therapy. Transplant Proc 1996;28:2825-6.
53.Ben-Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K,
Burroughs AK. Posttransplantation lymphoproliferative disorder in
liver recipients: characteristics, management, and outcome. Liver
Transpl  Surg 1999;5:184-91.
54.Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni
P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A. Anti-
B-cell monoclonal antibody treatment of severe posttransplant B-
lymphoproliferative disorder: prognostic factors and long-term
outcome. Blood 1998;92:3137-47.
55.Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB.
Treatment of posttransplant lymphoproliferative disorder with the
anti-CD20 monoclonal antibody rituximab alone in an adult after
liver transplantation: a new drug in therapy of patients with
posttransplant lymphoproliferative disorder after solid organ
transplantation? Transplantation 2000;69:430-2.
56.O'Brien S, Bernert RA, Logan JL, Lien YH. Remission of
posttransplant lymphoproliferative disorder after interferon alfa
therapy. J Am Soc Nephrol 1997;8:1483-9.
57.Schaar CG, van der Pijl JW, van Hoek B, de Fijter JW, Veenendaal
RA, Kluin PM, van Krieken JH, Hekman A, Terpstra WE, Willemze
R, Kluin-Nelemans HC. Successful outcome with a "quintuple
approach" of posttransplant lymphoproliferative disorder.
Transplantation 2001;71:47-52.
58.Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber
KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorder MI. Reduced
incidence of Epstein-Barr virus-associated posttransplant
lymphoproliferative disorder using preemptive antiviral therapy.
Transplantation 1997;64:848-52.
59.Bai X, Hosler G, Rogers BB, Dawson DB, Scheuermann RH.
Quantitative polymerase chain reaction for human herpesvirus
diagnosis and measurement of Epstein-Barr virus burden in
posttransplant lymphoproliferative disorder. Clin Chem 1997;43:
1843-9.
